RS
MRNA icon

R Squared’s Moderna MRNA Stock Holding History

R Squared’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-110
Closed -$4.57K – 1026
2024
Q4 		$4.57K Buy
+110
New +$5.26K ﹤0.01% 1332

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

R Squared's MRNA Position: Q1 2025 in Review

R Squared sold out of Moderna (MRNA) in Q1 2025, closing a stake of 110 shares — an estimated $4.57K sold.

R Squared first reported a position in MRNA in Q4 2024 and held it in 1 quarter. The position peaked at $4.57K in Q4 2024. 693 funds tracked by Wall St. Rank hold MRNA as of Q1 2025.

  • R Squared reported no remaining Moderna position as of Q1 2025 after selling out during the quarter.
  • R Squared sold 110 Moderna shares in Q1 2025, an estimated $4.57K.
  • R Squared first reported a position in Moderna in Q4 2024 and held it in 1 quarter.
  • R Squared's Moderna position peaked at $4.57K in Q4 2024.
  • 693 funds tracked by Wall St. Rank held Moderna as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.